Tin tức & Cập nhật
Xem bài viết Gan
Xem
Chỉ hiển thị Multimedia

Seladelpar extends benefit to PBC patients with compensated liver cirrhosis
20 Jun 2024
bởiAudrey Abella
An interim analysis of the open-label phase III ASSURE study finds benefit in seladelpar, a novel delpar (a potent and selective PPAR*-delta agonist), for individuals with primary biliary cholangitis (PBC) and compensated liver cirrhosis.
20 Jun 2024







